Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors

Shuang Ren, Juan Zeng, Ye Mei, John Zhang, S. Frank Yan, Jian Fei, Li Chen

Research output: Contribution to journalArticle

Abstract

Cytochrome P450 (CYP) 2J2 is one of the human CYPs involved in phase I xenobiotics metabolism. It is mainly expressed in extrahepatic tissues, including intestine and cardiovascular systems. The general role of CYP2J2 in drug metabolism is not yet fully understood, and the recent discovery that CYP2J2 can metabolize a wide range of structurally diverse drugs and its primary distribution in the intestine suggest its potentially indispensable role in first-pass intestinal metabolism and involvement in drug-drug interaction. To fully characterize its role in drug metabolism, selective and potent inhibitors of CYP2J2 are necessary tools. In the current study, 69 known drugs were screened for the inhibition of CYP2J2, and we discovered a number of marketed drugs as potent and selective CYP2J2 inhibitors. In particular, telmisartan and flunarizine have CYP2J2 inhibition IC50 values of 0.42 μM and 0.94 μM, respectively, which are at least 10-fold more selective against all other major metabolizing CYPs; moreover, they are not substrates of CYP2J2 and show no timedependent inhibition toward this CYP. The results of enzyme kinetics studies, supported by molecular modeling, have also elucidated that telmisartan is a mixed-type inhibitor, and flunarizine competitively inhibits CYP2J2. The Ki for telmisartan is 0.19 μM, with an α value, an indicator of the type of inhibition mechanism, of 2.80, and flunarizine has a K i value of 0.13 μM. These newly discovered CYP2J2 inhibitors can be potentially used as a tool to study CYP2J2 in drug metabolism and interaction in a clinical setting.

Original languageEnglish (US)
Pages (from-to)60-71
Number of pages12
JournalDrug Metabolism and Disposition
Volume41
Issue number1
DOIs
StatePublished - Jan 2013

Fingerprint

Cytochrome P-450 Enzyme System
Flunarizine
Pharmaceutical Preparations
Drug Interactions
Intestines
arachidonate epoxygenase
Xenobiotics
Cardiovascular System
Inhibitory Concentration 50
Enzymes

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors. / Ren, Shuang; Zeng, Juan; Mei, Ye; Zhang, John; Yan, S. Frank; Fei, Jian; Chen, Li.

In: Drug Metabolism and Disposition, Vol. 41, No. 1, 01.2013, p. 60-71.

Research output: Contribution to journalArticle

Ren, Shuang ; Zeng, Juan ; Mei, Ye ; Zhang, John ; Yan, S. Frank ; Fei, Jian ; Chen, Li. / Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors. In: Drug Metabolism and Disposition. 2013 ; Vol. 41, No. 1. pp. 60-71.
@article{9520c02fb888462e84457f3c09e3f919,
title = "Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors",
abstract = "Cytochrome P450 (CYP) 2J2 is one of the human CYPs involved in phase I xenobiotics metabolism. It is mainly expressed in extrahepatic tissues, including intestine and cardiovascular systems. The general role of CYP2J2 in drug metabolism is not yet fully understood, and the recent discovery that CYP2J2 can metabolize a wide range of structurally diverse drugs and its primary distribution in the intestine suggest its potentially indispensable role in first-pass intestinal metabolism and involvement in drug-drug interaction. To fully characterize its role in drug metabolism, selective and potent inhibitors of CYP2J2 are necessary tools. In the current study, 69 known drugs were screened for the inhibition of CYP2J2, and we discovered a number of marketed drugs as potent and selective CYP2J2 inhibitors. In particular, telmisartan and flunarizine have CYP2J2 inhibition IC50 values of 0.42 μM and 0.94 μM, respectively, which are at least 10-fold more selective against all other major metabolizing CYPs; moreover, they are not substrates of CYP2J2 and show no timedependent inhibition toward this CYP. The results of enzyme kinetics studies, supported by molecular modeling, have also elucidated that telmisartan is a mixed-type inhibitor, and flunarizine competitively inhibits CYP2J2. The Ki for telmisartan is 0.19 μM, with an α value, an indicator of the type of inhibition mechanism, of 2.80, and flunarizine has a K i value of 0.13 μM. These newly discovered CYP2J2 inhibitors can be potentially used as a tool to study CYP2J2 in drug metabolism and interaction in a clinical setting.",
author = "Shuang Ren and Juan Zeng and Ye Mei and John Zhang and Yan, {S. Frank} and Jian Fei and Li Chen",
year = "2013",
month = "1",
doi = "10.1124/dmd.112.048264",
language = "English (US)",
volume = "41",
pages = "60--71",
journal = "Drug Metabolism and Disposition",
issn = "0090-9556",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors

AU - Ren, Shuang

AU - Zeng, Juan

AU - Mei, Ye

AU - Zhang, John

AU - Yan, S. Frank

AU - Fei, Jian

AU - Chen, Li

PY - 2013/1

Y1 - 2013/1

N2 - Cytochrome P450 (CYP) 2J2 is one of the human CYPs involved in phase I xenobiotics metabolism. It is mainly expressed in extrahepatic tissues, including intestine and cardiovascular systems. The general role of CYP2J2 in drug metabolism is not yet fully understood, and the recent discovery that CYP2J2 can metabolize a wide range of structurally diverse drugs and its primary distribution in the intestine suggest its potentially indispensable role in first-pass intestinal metabolism and involvement in drug-drug interaction. To fully characterize its role in drug metabolism, selective and potent inhibitors of CYP2J2 are necessary tools. In the current study, 69 known drugs were screened for the inhibition of CYP2J2, and we discovered a number of marketed drugs as potent and selective CYP2J2 inhibitors. In particular, telmisartan and flunarizine have CYP2J2 inhibition IC50 values of 0.42 μM and 0.94 μM, respectively, which are at least 10-fold more selective against all other major metabolizing CYPs; moreover, they are not substrates of CYP2J2 and show no timedependent inhibition toward this CYP. The results of enzyme kinetics studies, supported by molecular modeling, have also elucidated that telmisartan is a mixed-type inhibitor, and flunarizine competitively inhibits CYP2J2. The Ki for telmisartan is 0.19 μM, with an α value, an indicator of the type of inhibition mechanism, of 2.80, and flunarizine has a K i value of 0.13 μM. These newly discovered CYP2J2 inhibitors can be potentially used as a tool to study CYP2J2 in drug metabolism and interaction in a clinical setting.

AB - Cytochrome P450 (CYP) 2J2 is one of the human CYPs involved in phase I xenobiotics metabolism. It is mainly expressed in extrahepatic tissues, including intestine and cardiovascular systems. The general role of CYP2J2 in drug metabolism is not yet fully understood, and the recent discovery that CYP2J2 can metabolize a wide range of structurally diverse drugs and its primary distribution in the intestine suggest its potentially indispensable role in first-pass intestinal metabolism and involvement in drug-drug interaction. To fully characterize its role in drug metabolism, selective and potent inhibitors of CYP2J2 are necessary tools. In the current study, 69 known drugs were screened for the inhibition of CYP2J2, and we discovered a number of marketed drugs as potent and selective CYP2J2 inhibitors. In particular, telmisartan and flunarizine have CYP2J2 inhibition IC50 values of 0.42 μM and 0.94 μM, respectively, which are at least 10-fold more selective against all other major metabolizing CYPs; moreover, they are not substrates of CYP2J2 and show no timedependent inhibition toward this CYP. The results of enzyme kinetics studies, supported by molecular modeling, have also elucidated that telmisartan is a mixed-type inhibitor, and flunarizine competitively inhibits CYP2J2. The Ki for telmisartan is 0.19 μM, with an α value, an indicator of the type of inhibition mechanism, of 2.80, and flunarizine has a K i value of 0.13 μM. These newly discovered CYP2J2 inhibitors can be potentially used as a tool to study CYP2J2 in drug metabolism and interaction in a clinical setting.

UR - http://www.scopus.com/inward/record.url?scp=84871539611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871539611&partnerID=8YFLogxK

U2 - 10.1124/dmd.112.048264

DO - 10.1124/dmd.112.048264

M3 - Article

C2 - 23033255

AN - SCOPUS:84871539611

VL - 41

SP - 60

EP - 71

JO - Drug Metabolism and Disposition

JF - Drug Metabolism and Disposition

SN - 0090-9556

IS - 1

ER -